We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncolytics Enters into Sponsorship Agreement with NCIC CTG
News

Oncolytics Enters into Sponsorship Agreement with NCIC CTG

Oncolytics Enters into Sponsorship Agreement with NCIC CTG
News

Oncolytics Enters into Sponsorship Agreement with NCIC CTG

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncolytics Enters into Sponsorship Agreement with NCIC CTG"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oncolytics Biotech Inc. has announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer.

"We are pleased to be conducting a second randomized study with the NCIC CTG," said Dr. Brad Thompson, President and CEO of Oncolytics.

Dr. Thompson continued, "This study will build on both our early preclinical and clinical colorectal cancer work, as well as preclinical research combining REOLYSIN with Avastin®. As a Company, we intend to continue expanding our clinical program to include randomized studies of frequently diagnosed cancers."

The study will be an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with FOLFOX-6 plus bevacizumab (Avastin) versus FOLFOX-6 plus bevacizumab alone.

Approximately 50 response evaluable patients will be enrolled in each arm, after a six to nine patient safety run in.

Advertisement